Xenetic Biosciences, Inc. (NASDAQ:XBIO) Sees Significant Decrease in Short Interest

Xenetic Biosciences, Inc. (NASDAQ:XBIO) saw a significant decrease in short interest in January. As of January 15th, there was short interest totaling 4,870 shares, a decrease of 23.8% from the December 31st total of 6,390 shares. Based on an average daily volume of 17,808 shares, the short-interest ratio is presently 0.3 days. Approximately 0.2% of the company’s shares are sold short. Approximately 0.2% of the company’s shares are sold short. Based on an average daily volume of 17,808 shares, the short-interest ratio is presently 0.3 days.

Xenetic Biosciences Stock Up 1.4%

Shares of XBIO stock opened at $2.25 on Tuesday. The firm has a 50 day moving average of $2.33 and a two-hundred day moving average of $3.02. The stock has a market capitalization of $5.15 million, a PE ratio of -1.10 and a beta of 2.29. Xenetic Biosciences has a 52 week low of $1.90 and a 52 week high of $13.93.

Xenetic Biosciences (NASDAQ:XBIO) last posted its quarterly earnings data on Wednesday, November 12th. The company reported ($0.33) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.49) by $0.16. The business had revenue of $1.03 million for the quarter. Xenetic Biosciences had a negative return on equity of 64.66% and a negative net margin of 110.42%. Analysts expect that Xenetic Biosciences will post -1.01 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Xenetic Biosciences in a research note on Wednesday, January 21st. One analyst has rated the stock with a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the company has a consensus rating of “Reduce”.

Hedge Funds Weigh In On Xenetic Biosciences

An institutional investor recently raised its position in Xenetic Biosciences stock. Sachetta LLC lifted its stake in shares of Xenetic Biosciences, Inc. (NASDAQ:XBIO) by 43.1% in the second quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 15,259 shares of the company’s stock after buying an additional 4,593 shares during the quarter. Sachetta LLC owned approximately 0.99% of Xenetic Biosciences worth $60,000 at the end of the most recent reporting period. Institutional investors own 15.12% of the company’s stock.

About Xenetic Biosciences

Xenetic Biosciences, Inc is a clinical-stage biotechnology company focused on the development and commercialization of enhanced protein and peptide therapeutics for oncology, immunology and rare diseases. The company leverages its proprietary platforms to extend the half-life, improve the stability and optimize the delivery of biopharmaceuticals. Xenetic’s pipeline includes novel candidates designed to address unmet medical needs in solid tumors and inherited disorders.

At the heart of Xenetic’s technology portfolio are two complementary platforms: PolyXen, which employs a unique polysialylation process to prolong drug circulation and reduce immunogenicity, and Alphabody, a next-generation antibody-mimetic framework engineered for high-affinity binding to challenging targets.